Innate Pharma’s ANKET® Abstract Selected for EHA 2025 Congress

Innate Pharma SA ( (FR:IPH) ) just unveiled an update.

Innate Pharma announced that its ANKET® abstract on IPH6501, targeting CD20 B cells in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for presentation at the European Hematology Association Congress 2025. This selection highlights the potential impact of IPH6501, which has shown superior anti-tumor efficacy in preclinical models, on the company’s position in the oncology sector and its ongoing commitment to advancing cancer immunotherapies.

The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK cell engagers, alongside developing antibody drug conjugates and monoclonal antibodies. Innate Pharma collaborates with major biopharmaceutical firms such as Sanofi and AstraZeneca to advance cancer treatment innovations.

Average Trading Volume: 169,713

Technical Sentiment Signal: Sell

Current Market Cap: €183.4M

Learn more about IPH stock on TipRanks’ Stock Analysis page.